Vaccinex was founded based on antibody platform technology developed at the University of Rochester Medical Center.
Vaccinex, Inc. is a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders. Its lead product candidate, pepinemab, is in clinical development for the treatment of Alzheimer’s disease and head and neck, pancreatic, and breast cancer.
Vaccinex has grown into a public company (Nasdaq: VCNX) with 40 employees, a $6.34 million market cap, and an annual revenue of $570,000. The company is poised to continue driving economic growth by advancing the development of targeted biotherapeutics for serious diseases, such as Alzheimer’s disease, cancer, and autoimmune disorders. Through its innovative research and clinical trials, Vaccinex not only improves treatment options but also creates jobs in the biotech sector and stimulates investment in cutting-edge medical technologies.